futuximab: Clinical Trials

11 trials of futuximab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated, 3 withdrawn. 8 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Completed 4, Terminated 2, Withdrawn 2
Phase 14Completed 2, Terminated 1, Withdrawn 1
Phase 32Terminated 1, Withdrawn 1

Follow futuximab: new trials by email Literature Review of futuximab trials Research Report on futuximab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
Futuximab/modotuximab, Trifluridine/Tipiracil - Metastatic Colorectal Cancer
Phase 3TerminatedInstitut de Recherches Internationales Servier72022-04-212024-08-20
Sym004 Versus TAS-102 in Patients With mCRC
Sym004, TAS-102 - Metastatic Colorectal Cancer, Colorectal Cancer Metastatic
Phase 3WithdrawnSymphogen A/S2019-02-012019-02-04
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Sym004, Futuximab, Modotuximab - Metastatic Colorectal Cancer, Colorectal Cancer Metastatic
Phase 2TerminatedSymphogen A/S22018-11-292020-09-28
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Sym004 - Metastatic Colorectal Cancer
Phase 2WithdrawnSymphogen A/S2016-12-012017-02-01
Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
Sym004, Nivolumab - Squamous Non-Small Cell Lung Cancer
Phase 1 / Phase 2WithdrawnSymphogen A/S2016-11-012017-08-28
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
Sym004, FOLFIRI - Metastatic Colorectal Cancer
Phase 1 / Phase 2TerminatedSymphogen A/S102016-03-152019-03-26
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Sym004 - 18 mg/kg, Sym004 - 24 mg/kg - Malignant Glioma
Phase 2CompletedAnnick Desjardins432016-02-012020-08-05
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC) - Metastatic Colorectal Cancer
Phase 2CompletedSymphogen A/S2542014-03-062019-04-16
Japanese Phase 1 Trial of Sym004 in Solid Tumors
Sym004 - Solid Tumors
Phase 1CompletedMerck KGaA, Darmstadt, Germany512013-10-312017-08-23
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Sym004 - Carcinoma, Squamous Cell of Head and Neck
Phase 2CompletedSymphogen A/S262011-07-012018-10-15
Sym004 in Patients With Advanced Solid Tumors
Sym004 - Metastatic Colorectal Cancer
Phase 1 / Phase 2CompletedSymphogen A/S1112010-03-012018-10-15

Conditions studied

Colorectal Neoplasms (7)  ·  Carcinoma (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Glioblastoma (1)  ·  Glioma (1)  ·  Neoplasm Metastasis (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Symphogen A/S (8)  ·  Annick Desjardins (1)  ·  Institut de Recherches Internationales Servier (1)  ·  Merck KGaA, Darmstadt, Germany (1)

Countries

United States (6)  ·  Belgium (4)  ·  Germany (4)  ·  Spain (4)  ·  France (2)  ·  Hungary (2)  ·  Italy (2)  ·  Austria (1)  ·  Denmark (1)  ·  Finland (1)  ·  Japan (1)  ·  Poland (1)  ·  Russia (1)

Top investigators

Josep Tabernero, MD, PhD (4)  ·  Annick Desjardins, MD, FRCPC (1)  ·  Fortunato Ciardiello (1)  ·  Ivan Horak, MD, FACP (1)  ·  Scott Kopetz, MD,PhD,FACP (1)

Results publications

PMID 25952795, PMID 25962717, PMID 30099818

NIH funding

2018 (2), 2009 (1), 2015 (1), 2016 (1)